Chrubasik S, Senninger N, Chrubasik J
Abteilung Innere Medizin I der Medizinischen Klinik, Universität Heidelberg.
Chirurg. 1996 Jul;67(7):665-70.
The advantages and disadvantages associated with epidural opioids require careful selection of the opioid and its dosage. There is presently no ideal opioid available for epidural use. Comparative pharmacokinetic data help to select the appropriate epidural opioid. Morphine (provided it is given in small doses and volumes) is very appropriate for epidural pain treatment, especially for longer periods of treatment, due to excellent analgesia and very low systemic morphine concentrations. The faster onset of analgesia with epidural pethidine, alfentanil und fentanyl make these opioids recommendable. However, due to the increased risk of respiratory depression during continuous treatment, these drugs should not be given over extended periods. Epidural administration of methadone, sufentanil und buprenorphine cannot be recommended since the advantages over systemic use do not outweigh the risks. Epidural tramadol may be useful in clinical routine, if opioids are not available and supervision of the patient is not guaranteed, because tramadol is not restricted by law and has a low potential for central depressive effects. The safety of the patients should be paramount. If patients are harmed by inappropriate opioids or dose regimens this will discredit a valuable for treating postoperative pain. Postoperative epidural dosages should be as low as possible and be titrated to the patient's individual needs for analgesia. Epidural morphine treatment is an alternative to step 4 of the WHO treatment regimen for patients with intractable pain or those suffering from systemic opioid side effects. Careful selection of patients helps to increase successful treatment. If implantable devices (ports or pumps, according to the life expectancy) are employed, the intrathecal route of administration is preferable to the epidural route, as the latter has a 10 times higher morphine dose requirement.
硬膜外使用阿片类药物的利弊要求谨慎选择阿片类药物及其剂量。目前尚无理想的可用于硬膜外的阿片类药物。比较药代动力学数据有助于选择合适的硬膜外阿片类药物。吗啡(前提是小剂量、小体积给药)非常适合硬膜外疼痛治疗,尤其是较长时间的治疗,因为其镇痛效果良好且全身吗啡浓度极低。硬膜外注射哌替啶、阿芬太尼和芬太尼起效更快,因此推荐使用这些阿片类药物。然而,由于持续治疗期间呼吸抑制风险增加,这些药物不应长期使用。不推荐硬膜外使用美沙酮、舒芬太尼和丁丙诺啡,因为与全身用药相比,其优势并不大于风险。如果没有阿片类药物且无法保证对患者进行监测,硬膜外使用曲马多在临床常规中可能有用,因为曲马多不受法律限制且中枢抑制作用潜力低。患者的安全应是首要的。如果患者因不适当的阿片类药物或剂量方案而受到伤害,这将损害术后疼痛治疗这一有价值的方法。术后硬膜外剂量应尽可能低,并根据患者个体镇痛需求进行滴定。对于顽固性疼痛患者或患有全身性阿片类药物副作用的患者,硬膜外吗啡治疗是世界卫生组织治疗方案第4步的替代方法。仔细选择患者有助于提高治疗成功率。如果使用可植入装置(根据预期寿命选择端口或泵),鞘内给药途径优于硬膜外途径,因为后者所需吗啡剂量高10倍。